Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $59.74 million. The enterprise value is -$49.79 million.

Market Cap	59.74M
Enterprise Value	-49.79M

Important Dates

The next estimated earnings date is Tuesday, May 7, 2024, before market open.

Earnings Date	May 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Rallybio has 37.81 million shares outstanding. The number of shares has increased by 27.11% in one year.

Shares Outstanding	37.81M
Shares Change (YoY)	+27.11%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	4.45%
Owned by Institutions (%)	87.17%
Float	21.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.56
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.39, with a Debt / Equity ratio of 0.00.

Current Ratio	12.39
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.90% and return on invested capital (ROIC) is -74.06%.

Return on Equity (ROE)	-56.90%
Return on Assets (ROA)	-53.40%
Return on Capital (ROIC)	-74.06%
Revenue Per Employee	n/a
Profits Per Employee	-$1.73M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.56% in the last 52 weeks. The beta is -1.64, so Rallybio's price volatility has been lower than the market average.

Beta (1Y)	-1.64
52-Week Price Change	-67.56%
50-Day Moving Average	1.80
200-Day Moving Average	3.22
Relative Strength Index (RSI)	45.16
Average Volume (30 Days)	1,634,996

Short Selling Information

The latest short interest is 1.31 million, so 3.47% of the outstanding shares have been sold short.

Short Interest	1.31M
Short Previous Month	1.28M
Short % of Shares Out	3.47%
Short % of Float	6.19%
Short Ratio (days to cover)	8.89

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-78.93M
Pretax Income	-74.56M
Net Income	-74.56M
EBITDA	-74.41M
EBIT	-74.56M
Earnings Per Share (EPS)	-$1.84

Full Income Statement

Balance Sheet

The company has $109.93 million in cash and $392,000 in debt, giving a net cash position of $109.54 million or $2.90 per share.

Cash & Cash Equivalents	109.93M
Total Debt	392,000
Net Cash	109.54M
Net Cash Per Share	$2.90
Equity / Book Value	106.18M
Book Value Per Share	2.81
Working Capital	105.53M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$60.27 million and capital expenditures -$12,000, giving a free cash flow of -$60.28 million.

Operating Cash Flow	-60.27M
Capital Expenditures	-12,000
Free Cash Flow	-60.28M
FCF Per Share	-$1.49

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.11%
Shareholder Yield	-27.11%
Earnings Yield	-124.81%
FCF Yield	-100.89%

Analyst Forecast

The average price target for Rallybio is $10.42, which is 559.49% higher than the current price. The consensus rating is "Buy".

Price Target	$10.42
Price Target Difference	559.49%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-1.53%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2